# Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions

> **NCT01723982** · PHASE2 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 256 (actual)

## Conditions studied

- Infertility

## Interventions

- **DRUG:** Barusiban (FE 200440)
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT01723982
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-10
- **Final completion:** 2015-05
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2015-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01723982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01723982, "Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01723982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*